Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Achim Rittmeyer"'
Autor:
David R. Gandara, S. Morris, A. Cardona, Julien Mazieres, Martin Reck, Marcus Ballinger, Diana Mendus, Denis Moro-Sibilot, Shirish M. Gadgeel, Achim Rittmeyer, Solange Peters
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 3 (2021)
Journal for immunotherapy of cancer, vol 9, iss 3
Journal for Immunotherapy of Cancer
Journal for immunotherapy of cancer, vol 9, iss 3
Journal for Immunotherapy of Cancer
BackgroundTreatment-induced accelerated tumor growth is a progression pattern reported with immune checkpoint inhibitors that has never been evaluated in randomized phase III studies because it requires two pretreatment scans. This study aimed to dev
Autor:
J. Goldschmidt, Keunchil Park, Filippo de Marinis, M. Gandhi, Paul Conkling, Achim Rittmeyer, Rimas V. Lukas, Joachim von Pawel, Shirish M. Gadgeel, Carol O'Hear, Marcus Ballinger, Alan Sandler, Diego Cortinovis, Sylvia Hu, Catherine Lai, Lou Fehrenbacher, Jyoti D. Patel
Publikováno v:
Lung Cancer. 128:105-112
Objectives To assess the safety and efficacy of atezolizumab and docetaxel in patients with and without a history of asymptomatic, treated brain metastases in the phase III OAK trial. Materials and methods Patients received 1200 mg atezolizumab or 75
Autor:
Birgit Zwerger, Achim Rittmeyer, Christian Reinhardt, Hans-Ulrich Schildhaus, Annett Schiwitza, Andreas Leha, Stefan Andreas, Josef Rüschoff
Publikováno v:
Immunotherapy. 11(9)
Aim: Radiological criteria alone do not reflect the entire population benefitting from checkpoint inhibitor therapy (CIT). This study aimed to detect patterns to assess CIT efficacy in non-small-cell lung cancer (NSCLC) patients. Materials & methods:
Autor:
Paul Conkling, J-Y. Han, M. Cobo, M. Gandhi, Denis Moro-Sibilot, Louis Fehrenbacher, Wei Yu, Rodolfo Bordoni, Hina Patel, Marcin Kowanetz, Alan Sandler, David R. Gandara, Kwang Bo Park, C. Matheny, J. von Pawel, Achim Rittmeyer, Marcus Ballinger, Toyoaki Hida, Miyako Satouchi
Publikováno v:
European journal of cancer (Oxford, England : 1990). 107
Background Atezolizumab (anti–programmed death-ligand 1 [PD-L1]) received approval from the US Food and Drug Administration and European Medicines Agency for previously treated advanced non–small-cell lung cancer based on OAK—a randomised, phas
Autor:
Sanne de Haas, Javier de Castro Carpeño, Pilar Garrido, Dariusz M. Kowalski, A. Villegas, Lisa H. Lam, Dolores Isla, Thomas E. Stinchcombe, Christina S. Baik, Rolf A. Stahel, Lukas Bubendorf, Marcello Tiseo, Michael W Lu, Christoph Meyenberg, Achim Rittmeyer, Solange Peters, Philip Bonomi
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 25(1)
Purpose: HER2-targeted therapy is not standard of care for HER2-positive non–small cell lung cancer (NSCLC). This phase II study investigated efficacy and safety of the HER2-targeted antibody–drug conjugate trastuzumab emtansine (T-DM1) in patien
Autor:
Ji Youn Han, Åslaug Helland, David R. Gandara, Keunchil Park, Toshio Kubo, J. Goldschmidt, Santiago Ponce Aix, Marcus Ballinger, Wei Yu, C. Matheny, Fabrice Barlesi, Alan Sandler, Richard Sullivan, M. Gandhi, Louis Fehrenbacher, Achim Rittmeyer, Joachim von Pawel, Cindy Yun, Julien Mazieres, Pei He
Publikováno v:
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer. 13(12)
Introduction Cancer immunotherapy may alter tumor biology such that treatment effects can extend beyond radiographic progression. In the randomized, phase III OAK study of atezolizumab (anti–programmed death-ligand 1) versus docetaxel in advanced N
Autor:
David Felix, Heigener, Gert, Hoeffken, Dieter, Wuerflein, Matthias, Feurer, Achim, Rittmeyer, Roland Maria, Huber, Markus, Pietsch, Arne, Ring, Karl-Matthias, Deppermann
Publikováno v:
Deutsche medizinische Wochenschrift (1946). 142(4)
Autor:
Martin Reck, Christos Chouaid, Vera Gorbunova, Anderson Loundou, Antonio Chella, H. T. Kim, Myung-Ju Ahn, Achim Rittmeyer, H. Groen, Antonio Pazzola, Joachim G.J.V. Aerts, Anders Vikström, Fabrice Barlesi, Jeong-Ho Kim, Claire Morando, Arnaud Scherpereel, Radj Gervais
Publikováno v:
Annals of Oncology, 25(5), 1044-1052. Oxford University Press
Annals of Oncology, 25(5), 1044-1052. Elsevier Ltd.
Annals of Oncology, 25(5), 1044-1052. Elsevier Ltd.
The randomized, phase III AVAPERL trial evaluated the safety and efficacy of bevacizumab maintenance with or without pemetrexed in nonsquamous nonsmall-cell lung cancer (nsNSCLC). Progression-free survival (PFS) was significantly prolonged with bevac
Autor:
Louis, Fehrenbacher, Alexander, Spira, Marcus, Ballinger, Marcin, Kowanetz, Johan, Vansteenkiste, Julien, Mazieres, Keunchil, Park, David, Smith, Angel, Artal-Cortes, Conrad, Lewanski, Fadi, Braiteh, Daniel, Waterkamp, Pei, He, Wei, Zou, Daniel S, Chen, Jing, Yi, Alan, Sandler, Achim, Rittmeyer, Charles, Weissman
Publikováno v:
Lancet (London, England). 387(10030)
Outcomes are poor for patients with previously treated, advanced or metastatic non-small-cell lung cancer (NSCLC). The anti-programmed death ligand 1 (PD-L1) antibody atezolizumab is clinically active against cancer, including NSCLC, especially cance
Autor:
David R. Gandara, Fred R. Hirsch, Ramaswamy Govindan, See Phan, Thomas Cosgriff, Fadi Braiteh, Cristobal Belda-Iniesta, Dolores Isla, Achim Rittmeyer, Masamichi Ueda, Zanete Zvirbule, Michelle Boyer
Publikováno v:
Clinical lung cancer. 18(1)
Introduction The treatment options for squamous cell non–small-cell lung cancer (NSCLC) are limited. We assessed the efficacy and safety of onartuzumab plus platinum-doublet chemotherapy in previously untreated advanced squamous cell NSCLC. Patient